212 related articles for article (PubMed ID: 24754565)
1. Translating cell-based regenerative medicines from research to successful products: challenges and solutions.
Bayon Y; Vertès AA; Ronfard V; Egloff M; Snykers S; Salinas GF; Thomas R; Girling A; Lilford R; Clermont G; Kemp P
Tissue Eng Part B Rev; 2014 Aug; 20(4):246-56. PubMed ID: 24754565
[TBL] [Abstract][Full Text] [Related]
2. How Regenerative Medicine Stakeholders Adapt to Ever-Changing Technology and Regulatory Challenges? Snapshots from the World TERMIS Industry Symposium (September 10, 2015, Boston).
Bayon Y; Van Dyke M; Buelher R; Tubo R; Bertram T; Malfroy-Camine B; Rathman M; Ronfard V
Tissue Eng Part B Rev; 2017 Apr; 23(2):159-162. PubMed ID: 27771996
[TBL] [Abstract][Full Text] [Related]
3. Turning Regenerative Medicine Breakthrough Ideas and Innovations into Commercial Products.
Bayon Y; Vertès AA; Ronfard V; Culme-Seymour E; Mason C; Stroemer P; Najimi M; Sokal E; Wilson C; Barone J; Aras R; Chiesi A
Tissue Eng Part B Rev; 2015 Dec; 21(6):560-71. PubMed ID: 26179129
[TBL] [Abstract][Full Text] [Related]
4. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
[TBL] [Abstract][Full Text] [Related]
5. The early career researcher's toolkit: translating tissue engineering, regenerative medicine and cell therapy products.
Rafiq QA; Ortega I; Jenkins SI; Wilson SL; Patel AK; Barnes AL; Adams CF; Delcassian D; Smith D
Regen Med; 2015 Nov; 10(8):989-1003. PubMed ID: 26628407
[TBL] [Abstract][Full Text] [Related]
6. Enhancing Tissue Engineering and Regenerative Medicine Product Commercialization: The Role of Science in Regulatory Decision-Making for the TE/RM Product Development.
Bertram TA; Johnson PC; Tawil BJ; Van Dyke M; Hellman KB
Tissue Eng Part A; 2015 Oct; 21(19-20):2476-9. PubMed ID: 26222734
[TBL] [Abstract][Full Text] [Related]
7. Awareness of the role of science in the FDA regulatory submission process: a survey of the TERMIS-Americas membership.
Johnson PC; Bertram TA; Carty NR; Hellman KB; Tawil BJ; Van Dyke M
Tissue Eng Part A; 2014 Jun; 20(11-12):1565-82. PubMed ID: 24665855
[TBL] [Abstract][Full Text] [Related]
8. Hurdles in tissue engineering/regenerative medicine product commercialization: a survey of North American academia and industry.
Johnson PC; Bertram TA; Tawil B; Hellman KB
Tissue Eng Part A; 2011 Jan; 17(1-2):5-15. PubMed ID: 20726816
[TBL] [Abstract][Full Text] [Related]
9. Manufacturing road map for tissue engineering and regenerative medicine technologies.
Hunsberger J; Harrysson O; Shirwaiker R; Starly B; Wysk R; Cohen P; Allickson J; Yoo J; Atala A
Stem Cells Transl Med; 2015 Feb; 4(2):130-5. PubMed ID: 25575525
[TBL] [Abstract][Full Text] [Related]
10. Innovative regenerative medicines in the EU: a better future in evidence?
Corbett MS; Webster A; Hawkins R; Woolacott N
BMC Med; 2017 Mar; 15(1):49. PubMed ID: 28270209
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the Past, Present, and Future of Regenerative Medicine: A Global View.
Ronfard V; Vertès AA; May MH; Dupraz A; van Dyke ME; Bayon Y
Tissue Eng Part B Rev; 2017 Apr; 23(2):199-210. PubMed ID: 27762892
[TBL] [Abstract][Full Text] [Related]
12. Translating Dental, Oral, and Craniofacial Regenerative Medicine Innovations to the Clinic through Interdisciplinary Commercial Translation Architecture.
Taylor DP; Yoshida M; Fuller K; Giannobile WV; Sfeir CS; Wagner WR; Kohn DH
J Dent Res; 2021 Sep; 100(10):1039-1046. PubMed ID: 33906502
[TBL] [Abstract][Full Text] [Related]
13. Regenerative medicine, resource and regulation: lessons learned from the remedi project.
Ginty PJ; Rayment EA; Hourd P; Williams DJ
Regen Med; 2011 Mar; 6(2):241-53. PubMed ID: 21391857
[TBL] [Abstract][Full Text] [Related]
14. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
15. Regenerative Medicine Venturing at the University-Industry Boundary: Implications for Institutions, Entrepreneurs, and Industry.
Bock AJ; Johnson D
Adv Exp Med Biol; 2018; 1098():213-236. PubMed ID: 30238374
[TBL] [Abstract][Full Text] [Related]
16. The translation of cell-based therapies: clinical landscape and manufacturing challenges.
Heathman TR; Nienow AW; McCall MJ; Coopman K; Kara B; Hewitt CJ
Regen Med; 2015; 10(1):49-64. PubMed ID: 25562352
[TBL] [Abstract][Full Text] [Related]
17. A changing time: the International Society for Cellular Therapy embraces its industry members.
Deans R; Gunter KC; Allsopp T; Bonyhadi M; Burger SR; Carpenter M; Clark T; Cox CS; Driscoll D; Field E; Huss R; Lardenoije R; Lodie TA; Mason C; Neubiser R; Rasko JE; Rowley J; Maziarz RT
Cytotherapy; 2010 Nov; 12(7):853-6. PubMed ID: 20942603
[TBL] [Abstract][Full Text] [Related]
18. Current understanding and challenges in bioprocessing of stem cell-based therapies for regenerative medicine.
Ratcliffe E; Thomas RJ; Williams DJ
Br Med Bull; 2011; 100():137-55. PubMed ID: 21852279
[TBL] [Abstract][Full Text] [Related]
19. Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products.
Hourd P; Chandra A; Alvey D; Ginty P; McCall M; Ratcliffe E; Rayment E; Williams DJ
Regen Med; 2014; 9(6):799-815. PubMed ID: 25431916
[TBL] [Abstract][Full Text] [Related]
20. The Cell Therapy Catapult: growing a U.K. cell therapy industry generating health and wealth.
Thompson K; Foster EP
Stem Cells Dev; 2013 Dec; 22 Suppl 1():35-9. PubMed ID: 24304073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
